Русский
Experience with populin with dihydroquercetin in novel coronavirus infection
DOI: https://dx.doi.org/10.18565/epidem.2022.12.2.77-82
Makashova V.V., Ponezheva Zh.B., Omarova Kh.G., Burkova V.N., Sergun V.P., Gorelov A.V.
1) Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2) OOO “BIOLIT”, Tomsk, Russia; 3) A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
Subjects and methods. Sixty patients diagnosed with COVID-19 in the early stage of convalescence were followed up. Thirty persons of them took populin with dihydroquercetin (a study group), the other 30 patients received basic therapy (a comparison group). The mean age was 52.08±11.9 years. There was a female preponderance in both groups.
Results. The incorporation of populin with dihydroquercetin into the combination therapy of patients with COVID-19 contributed to a faster normalization of clinical and laboratory parameters and to a significantly rapid rise in SARS-CoV-2 IgG antibody titers. The drug contributed to a more rapid normalization of the inflammatory process in the lungs, as evidenced by computed tomography.
Conclusion. It is advisable to incorporate BAA populin with dihydroquercetin into the combination treatment of patients with COVID-19.
Literature
1. Ханин А.Л., Буркова В.Н., Стрелис А.К., Викторова И.Б. и др. Методические рекомендации по клиническому исследованию лечебного эффекта препарата Популин при туберкулезе легких. Томск, 2006. 16 с. Khanin A.L., Burkova V.N., Strelis A.K., Viktorova I.B. et al. [Methodological recommendations for the clinical study of the therapeutic effect of the drug Populin in pulmonary tuberculosis]. Tomsk, 2006. 16 р. (In Russ.). 2. Ханин А.Л., Викторова И.Б. Популин в комплексном лечении больных туберкулезом легких: учебно-методическое пособие для врачей. Новокузнецк, 2010. 44 с. Khanin A.L., Viktorova I.B. [Populin in the complex treatment of patients with pulmonary tuberculosis: an educational and methodological guide for doctors]. Novokuznetsk, 2010. 44 p. (In Russ.). 3. Буркова В.Н., Иванов А.А., Сергун В.П. Осина в доказательной медицине XXI века. Томск, 2020: 94–107. Burkova V.N., Ivanov A.A., Sergun V.P. [Osina in evidence-based medicine of the XXI century]. Tomsk, 2020: 94–107. (In Russ.).
About the Autors
Professor Vera V. Makashova, MD, Leading Researcher, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Well-Being, Moscow, Russia; veramakashova@yandex.ru; https://orcid.org/0000-0002-0982-3527
Zhanna B. Ponezheva, MD, Head, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; doktorim@mail.ru; https://orcid.org/0000-0002-6539-4878
Khadizhat G. Omarova, Cand. Med. Sci., Head, Clinical Research Department, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; omarova71@inbox.ru; https://orcid.org/0000-0002-9682-2230
Valentina N. Burkova, ChD, Academician of the Russian Academy of Natural Sciences, Director for Science and Innovations; OOO «Biolit», Tomsk, Russia; info@biolit.info
Valery P. Sergun, Cand. Chem. Sci., Director, OOO «Biolit», Tomsk, Russia; info@biolit.info
Professor Aleksandr V. Gorelov, MD, Academician of the Russian Academy of Sciences; Deputy Director for Science, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Head, Department of Infectious Diseases and Epidemiology, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia; crie@pcr.ru; https://orcid.org/0000-0001-9257-0171
Similar Articles
